Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease
Abstract Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to low bone turnover. T...
Gespeichert in:
Veröffentlicht in: | Clinical Kidney Journal 2019-04, Vol.12 (2), p.269-280 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 280 |
---|---|
container_issue | 2 |
container_start_page | 269 |
container_title | Clinical Kidney Journal |
container_volume | 12 |
creator | Ureña-Torres, Pablo A Vervloet, Marc Mazzaferro, Sandro Oury, Franck Brandenburg, Vincent Bover, Jordi Cavalier, Etienne Cohen-Solal, Martine Covic, Adrian Drüeke, Tilman B Hindié, Elif Evenepoel, Pieter Frazão, João Goldsmith, David Kazama, Junichiro James Cozzolino, Mario Massy, Ziad A |
description | Abstract
Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to low bone turnover. The present article summarizes the important subjects that were covered during 'The Parathyroid Day in Chronic Kidney Disease' CME course organized in Paris in September 2017. It includes the latest insights on parathyroid gland growth, parathyroid hormone (PTH) synthesis, secretion and regulation by the calcium-sensing receptor, vitamin D receptor and fibroblast growth factor 23 (FGF23)-Klotho axis, as well as on parathyroid glands imaging. The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH levels at these stages might not be recommended. The effects of PTH on the central nervous system, in particular cognitive functions, and on the cardiovascular system are revised, and the reliability and exchangeability of second- and third-generation PTH immunoassays discussed. The article also reviews the different circulating biomarkers used for the diagnosis and monitoring of CKD-MBD, including PTH and alkaline phosphatases isoforms. Moreover, it presents an update on the control of SHPT by vitamin D compounds, old and new calcimimetics, and parathyroidectomy. Finally, it covers the latest insights on the persistence and de novo occurrence of SHPT in renal transplant recipients. |
doi_str_mv | 10.1093/ckj/sfy061 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6452197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A613867074</galeid><oup_id>10.1093/ckj/sfy061</oup_id><sourcerecordid>A613867074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c519t-3d08ce76b42c8229070af594cc4f6bd12ecc165711a378878eb20966c547476f3</originalsourceid><addsrcrecordid>eNp9kt1r1TAYxosobszd-AdIQAQRzpakaT68EMaZXzjUi3kd0_Rtm9k2NWkP9L83Z52HDcTkIi_J73ny9WTZc4LPCFb5uf11cx7rBXPyKDummMmNLEj--FDj4ig7jfEGp5ZWMCueZkc5VoIzLI-zn1_9DjrkhuiadoqpmDwaTTBTuwTvKtT60PsB3qIAow8T8jW6bgF9v4dcmiXp0LYNfnAWfXHVAAu6dBFMhGfZk9p0EU7vxpPsx4f319tPm6tvHz9vL642tiBq2uQVlhYELxm1klKFBTZ1oZi1rOZlRShYS3ghCDG5kFJIKClWnNuCCSZ4nZ9k71bfcS57qCwMUzCdHoPrTVi0N04_XBlcqxu_05wVlCiRDPLVoHPQgPahdHpHb4W39dw12lhdgqaUS00ZEwIn1eu7bYP_PUOcdO-iha4zA_g5JharQklBWEJfrmhjOtBuqH06h93j-oKTXHKBxZ46-weVegW9s-knapfmHwjerAIbfIwB6sOdCdb7iOgUEb1GJMEv7r_SAf0biAS8WgE_j_8z-gNKWMNn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2209598714</pqid></control><display><type>article</type><title>Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ureña-Torres, Pablo A ; Vervloet, Marc ; Mazzaferro, Sandro ; Oury, Franck ; Brandenburg, Vincent ; Bover, Jordi ; Cavalier, Etienne ; Cohen-Solal, Martine ; Covic, Adrian ; Drüeke, Tilman B ; Hindié, Elif ; Evenepoel, Pieter ; Frazão, João ; Goldsmith, David ; Kazama, Junichiro James ; Cozzolino, Mario ; Massy, Ziad A</creator><creatorcontrib>Ureña-Torres, Pablo A ; Vervloet, Marc ; Mazzaferro, Sandro ; Oury, Franck ; Brandenburg, Vincent ; Bover, Jordi ; Cavalier, Etienne ; Cohen-Solal, Martine ; Covic, Adrian ; Drüeke, Tilman B ; Hindié, Elif ; Evenepoel, Pieter ; Frazão, João ; Goldsmith, David ; Kazama, Junichiro James ; Cozzolino, Mario ; Massy, Ziad A ; ERA-EDTA CKD-MBD Working Group ; ERA-EDTA CKD-MBD Working Group</creatorcontrib><description>Abstract
Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to low bone turnover. The present article summarizes the important subjects that were covered during 'The Parathyroid Day in Chronic Kidney Disease' CME course organized in Paris in September 2017. It includes the latest insights on parathyroid gland growth, parathyroid hormone (PTH) synthesis, secretion and regulation by the calcium-sensing receptor, vitamin D receptor and fibroblast growth factor 23 (FGF23)-Klotho axis, as well as on parathyroid glands imaging. The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH levels at these stages might not be recommended. The effects of PTH on the central nervous system, in particular cognitive functions, and on the cardiovascular system are revised, and the reliability and exchangeability of second- and third-generation PTH immunoassays discussed. The article also reviews the different circulating biomarkers used for the diagnosis and monitoring of CKD-MBD, including PTH and alkaline phosphatases isoforms. Moreover, it presents an update on the control of SHPT by vitamin D compounds, old and new calcimimetics, and parathyroidectomy. Finally, it covers the latest insights on the persistence and de novo occurrence of SHPT in renal transplant recipients.</description><identifier>ISSN: 2048-8505</identifier><identifier>ISSN: 2048-8513</identifier><identifier>EISSN: 2048-8513</identifier><identifier>DOI: 10.1093/ckj/sfy061</identifier><identifier>PMID: 30976408</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Biological markers ; calcium ; Central nervous system ; Chronic kidney failure ; CKD ; CKD-Mbd ; Diseases ; EDTA ; Fibroblast growth factors ; Health aspects ; Hormones ; Human health sciences ; Hyperparathyroidism ; Kidney diseases ; Laboratory medicine & medical technology ; Médecine de laboratoire & technologie médicale ; Organ transplant recipients ; Parathyroid hormones ; phosphataemia ; Phosphatases ; Physiological aspects ; Sciences de la santé humaine ; Urologie & néphrologie ; Urology & nephrology ; Vitamin D ; Vitamins</subject><ispartof>Clinical Kidney Journal, 2019-04, Vol.12 (2), p.269-280</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. 2018</rights><rights>COPYRIGHT 2019 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c519t-3d08ce76b42c8229070af594cc4f6bd12ecc165711a378878eb20966c547476f3</citedby><cites>FETCH-LOGICAL-c519t-3d08ce76b42c8229070af594cc4f6bd12ecc165711a378878eb20966c547476f3</cites><orcidid>0000-0003-4607-9415</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452197/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452197/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30976408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ureña-Torres, Pablo A</creatorcontrib><creatorcontrib>Vervloet, Marc</creatorcontrib><creatorcontrib>Mazzaferro, Sandro</creatorcontrib><creatorcontrib>Oury, Franck</creatorcontrib><creatorcontrib>Brandenburg, Vincent</creatorcontrib><creatorcontrib>Bover, Jordi</creatorcontrib><creatorcontrib>Cavalier, Etienne</creatorcontrib><creatorcontrib>Cohen-Solal, Martine</creatorcontrib><creatorcontrib>Covic, Adrian</creatorcontrib><creatorcontrib>Drüeke, Tilman B</creatorcontrib><creatorcontrib>Hindié, Elif</creatorcontrib><creatorcontrib>Evenepoel, Pieter</creatorcontrib><creatorcontrib>Frazão, João</creatorcontrib><creatorcontrib>Goldsmith, David</creatorcontrib><creatorcontrib>Kazama, Junichiro James</creatorcontrib><creatorcontrib>Cozzolino, Mario</creatorcontrib><creatorcontrib>Massy, Ziad A</creatorcontrib><creatorcontrib>ERA-EDTA CKD-MBD Working Group</creatorcontrib><creatorcontrib>ERA-EDTA CKD-MBD Working Group</creatorcontrib><title>Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease</title><title>Clinical Kidney Journal</title><addtitle>Clin Kidney J</addtitle><description>Abstract
Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to low bone turnover. The present article summarizes the important subjects that were covered during 'The Parathyroid Day in Chronic Kidney Disease' CME course organized in Paris in September 2017. It includes the latest insights on parathyroid gland growth, parathyroid hormone (PTH) synthesis, secretion and regulation by the calcium-sensing receptor, vitamin D receptor and fibroblast growth factor 23 (FGF23)-Klotho axis, as well as on parathyroid glands imaging. The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH levels at these stages might not be recommended. The effects of PTH on the central nervous system, in particular cognitive functions, and on the cardiovascular system are revised, and the reliability and exchangeability of second- and third-generation PTH immunoassays discussed. The article also reviews the different circulating biomarkers used for the diagnosis and monitoring of CKD-MBD, including PTH and alkaline phosphatases isoforms. Moreover, it presents an update on the control of SHPT by vitamin D compounds, old and new calcimimetics, and parathyroidectomy. Finally, it covers the latest insights on the persistence and de novo occurrence of SHPT in renal transplant recipients.</description><subject>Biological markers</subject><subject>calcium</subject><subject>Central nervous system</subject><subject>Chronic kidney failure</subject><subject>CKD</subject><subject>CKD-Mbd</subject><subject>Diseases</subject><subject>EDTA</subject><subject>Fibroblast growth factors</subject><subject>Health aspects</subject><subject>Hormones</subject><subject>Human health sciences</subject><subject>Hyperparathyroidism</subject><subject>Kidney diseases</subject><subject>Laboratory medicine & medical technology</subject><subject>Médecine de laboratoire & technologie médicale</subject><subject>Organ transplant recipients</subject><subject>Parathyroid hormones</subject><subject>phosphataemia</subject><subject>Phosphatases</subject><subject>Physiological aspects</subject><subject>Sciences de la santé humaine</subject><subject>Urologie & néphrologie</subject><subject>Urology & nephrology</subject><subject>Vitamin D</subject><subject>Vitamins</subject><issn>2048-8505</issn><issn>2048-8513</issn><issn>2048-8513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kt1r1TAYxosobszd-AdIQAQRzpakaT68EMaZXzjUi3kd0_Rtm9k2NWkP9L83Z52HDcTkIi_J73ny9WTZc4LPCFb5uf11cx7rBXPyKDummMmNLEj--FDj4ig7jfEGp5ZWMCueZkc5VoIzLI-zn1_9DjrkhuiadoqpmDwaTTBTuwTvKtT60PsB3qIAow8T8jW6bgF9v4dcmiXp0LYNfnAWfXHVAAu6dBFMhGfZk9p0EU7vxpPsx4f319tPm6tvHz9vL642tiBq2uQVlhYELxm1klKFBTZ1oZi1rOZlRShYS3ghCDG5kFJIKClWnNuCCSZ4nZ9k71bfcS57qCwMUzCdHoPrTVi0N04_XBlcqxu_05wVlCiRDPLVoHPQgPahdHpHb4W39dw12lhdgqaUS00ZEwIn1eu7bYP_PUOcdO-iha4zA_g5JharQklBWEJfrmhjOtBuqH06h93j-oKTXHKBxZ46-weVegW9s-knapfmHwjerAIbfIwB6sOdCdb7iOgUEb1GJMEv7r_SAf0biAS8WgE_j_8z-gNKWMNn</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Ureña-Torres, Pablo A</creator><creator>Vervloet, Marc</creator><creator>Mazzaferro, Sandro</creator><creator>Oury, Franck</creator><creator>Brandenburg, Vincent</creator><creator>Bover, Jordi</creator><creator>Cavalier, Etienne</creator><creator>Cohen-Solal, Martine</creator><creator>Covic, Adrian</creator><creator>Drüeke, Tilman B</creator><creator>Hindié, Elif</creator><creator>Evenepoel, Pieter</creator><creator>Frazão, João</creator><creator>Goldsmith, David</creator><creator>Kazama, Junichiro James</creator><creator>Cozzolino, Mario</creator><creator>Massy, Ziad A</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>Q33</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4607-9415</orcidid></search><sort><creationdate>20190401</creationdate><title>Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease</title><author>Ureña-Torres, Pablo A ; Vervloet, Marc ; Mazzaferro, Sandro ; Oury, Franck ; Brandenburg, Vincent ; Bover, Jordi ; Cavalier, Etienne ; Cohen-Solal, Martine ; Covic, Adrian ; Drüeke, Tilman B ; Hindié, Elif ; Evenepoel, Pieter ; Frazão, João ; Goldsmith, David ; Kazama, Junichiro James ; Cozzolino, Mario ; Massy, Ziad A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c519t-3d08ce76b42c8229070af594cc4f6bd12ecc165711a378878eb20966c547476f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biological markers</topic><topic>calcium</topic><topic>Central nervous system</topic><topic>Chronic kidney failure</topic><topic>CKD</topic><topic>CKD-Mbd</topic><topic>Diseases</topic><topic>EDTA</topic><topic>Fibroblast growth factors</topic><topic>Health aspects</topic><topic>Hormones</topic><topic>Human health sciences</topic><topic>Hyperparathyroidism</topic><topic>Kidney diseases</topic><topic>Laboratory medicine & medical technology</topic><topic>Médecine de laboratoire & technologie médicale</topic><topic>Organ transplant recipients</topic><topic>Parathyroid hormones</topic><topic>phosphataemia</topic><topic>Phosphatases</topic><topic>Physiological aspects</topic><topic>Sciences de la santé humaine</topic><topic>Urologie & néphrologie</topic><topic>Urology & nephrology</topic><topic>Vitamin D</topic><topic>Vitamins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ureña-Torres, Pablo A</creatorcontrib><creatorcontrib>Vervloet, Marc</creatorcontrib><creatorcontrib>Mazzaferro, Sandro</creatorcontrib><creatorcontrib>Oury, Franck</creatorcontrib><creatorcontrib>Brandenburg, Vincent</creatorcontrib><creatorcontrib>Bover, Jordi</creatorcontrib><creatorcontrib>Cavalier, Etienne</creatorcontrib><creatorcontrib>Cohen-Solal, Martine</creatorcontrib><creatorcontrib>Covic, Adrian</creatorcontrib><creatorcontrib>Drüeke, Tilman B</creatorcontrib><creatorcontrib>Hindié, Elif</creatorcontrib><creatorcontrib>Evenepoel, Pieter</creatorcontrib><creatorcontrib>Frazão, João</creatorcontrib><creatorcontrib>Goldsmith, David</creatorcontrib><creatorcontrib>Kazama, Junichiro James</creatorcontrib><creatorcontrib>Cozzolino, Mario</creatorcontrib><creatorcontrib>Massy, Ziad A</creatorcontrib><creatorcontrib>ERA-EDTA CKD-MBD Working Group</creatorcontrib><creatorcontrib>ERA-EDTA CKD-MBD Working Group</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Kidney Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ureña-Torres, Pablo A</au><au>Vervloet, Marc</au><au>Mazzaferro, Sandro</au><au>Oury, Franck</au><au>Brandenburg, Vincent</au><au>Bover, Jordi</au><au>Cavalier, Etienne</au><au>Cohen-Solal, Martine</au><au>Covic, Adrian</au><au>Drüeke, Tilman B</au><au>Hindié, Elif</au><au>Evenepoel, Pieter</au><au>Frazão, João</au><au>Goldsmith, David</au><au>Kazama, Junichiro James</au><au>Cozzolino, Mario</au><au>Massy, Ziad A</au><aucorp>ERA-EDTA CKD-MBD Working Group</aucorp><aucorp>ERA-EDTA CKD-MBD Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease</atitle><jtitle>Clinical Kidney Journal</jtitle><addtitle>Clin Kidney J</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>12</volume><issue>2</issue><spage>269</spage><epage>280</epage><pages>269-280</pages><issn>2048-8505</issn><issn>2048-8513</issn><eissn>2048-8513</eissn><abstract>Abstract
Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to low bone turnover. The present article summarizes the important subjects that were covered during 'The Parathyroid Day in Chronic Kidney Disease' CME course organized in Paris in September 2017. It includes the latest insights on parathyroid gland growth, parathyroid hormone (PTH) synthesis, secretion and regulation by the calcium-sensing receptor, vitamin D receptor and fibroblast growth factor 23 (FGF23)-Klotho axis, as well as on parathyroid glands imaging. The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH levels at these stages might not be recommended. The effects of PTH on the central nervous system, in particular cognitive functions, and on the cardiovascular system are revised, and the reliability and exchangeability of second- and third-generation PTH immunoassays discussed. The article also reviews the different circulating biomarkers used for the diagnosis and monitoring of CKD-MBD, including PTH and alkaline phosphatases isoforms. Moreover, it presents an update on the control of SHPT by vitamin D compounds, old and new calcimimetics, and parathyroidectomy. Finally, it covers the latest insights on the persistence and de novo occurrence of SHPT in renal transplant recipients.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30976408</pmid><doi>10.1093/ckj/sfy061</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4607-9415</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2048-8505 |
ispartof | Clinical Kidney Journal, 2019-04, Vol.12 (2), p.269-280 |
issn | 2048-8505 2048-8513 2048-8513 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6452197 |
source | DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Biological markers calcium Central nervous system Chronic kidney failure CKD CKD-Mbd Diseases EDTA Fibroblast growth factors Health aspects Hormones Human health sciences Hyperparathyroidism Kidney diseases Laboratory medicine & medical technology Médecine de laboratoire & technologie médicale Organ transplant recipients Parathyroid hormones phosphataemia Phosphatases Physiological aspects Sciences de la santé humaine Urologie & néphrologie Urology & nephrology Vitamin D Vitamins |
title | Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A58%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20insights%20into%20parathyroid%20hormone:%20report%20of%20The%20Parathyroid%20Day%20in%20Chronic%20Kidney%20Disease&rft.jtitle=Clinical%20Kidney%20Journal&rft.au=Ure%C3%B1a-Torres,%20Pablo%20A&rft.aucorp=ERA-EDTA%20CKD-MBD%20Working%20Group&rft.date=2019-04-01&rft.volume=12&rft.issue=2&rft.spage=269&rft.epage=280&rft.pages=269-280&rft.issn=2048-8505&rft.eissn=2048-8513&rft_id=info:doi/10.1093/ckj/sfy061&rft_dat=%3Cgale_pubme%3EA613867074%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2209598714&rft_id=info:pmid/30976408&rft_galeid=A613867074&rft_oup_id=10.1093/ckj/sfy061&rfr_iscdi=true |